Megan Boston
Known title: Executive DirectorCIK: 0001808923
Associated companies
Transaction History
| BNTC | ▲ Buy | Open Market | 25,907 | — | 8/11/2023 | View on chart |
| BNTC | ▲ Buy | Open Market | 25,907 | — | 8/11/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Benitec Biopharma shares fell 23.9% over four weeks
Benitec Biopharma's stock dropped 23.9% over the past four weeks, according to a recent Yahoo article. The piece outlines factors that could help the price recover, noting the low RSI of 26.9 and the stock's proximity to a well‑tested support level at $10.89. The company’s average analyst target is $24.33, well above its current range.
Benitec Biopharma shares fell 23.9% over four weeks. Benitec Biopharma's stock dropped 23.9% over the past four weeks, according to a recent Yahoo article. The piece outlines factors that could help the price recover, noting the low RSI of 26.9 and the stock's proximity to a well‑tested support level at $10.89. The company’s average analyst target is $24.33, well above its current range.